联合检测血清APE1、miR183在原发性肝癌诊断中的价值

肝脏 ›› 2024, Vol. 29 ›› Issue (12): 1498-1502.

联合检测血清APE1、miR183在原发性肝癌诊断中的价值

菅辉玲, 高丽霞, 李桂圆, 朱海鹏, 李砥, 贾晓玲, 胡军

834000 新疆克拉玛依市中心医院血液肿瘤科,新疆消化系统肿瘤精准医疗临床医学研究中心,新疆临床基因检测与生物医学信息重点实验室(菅辉玲,高丽霞,朱海鹏,李砥,贾晓玲,胡军); 200065 上海同济医院肿瘤内科(李桂圆)

收稿日期:2023-09-30 出版日期:2024-12-31 发布日期:2025-02-19
通讯作者: 胡军
基金资助:
新疆维吾尔自治区自然科学基金资助项目(2020D01A16)

The diagnostic value of combined detection of serum APE1 and miR183 in primary hepatocellular carcinoma

JIAN Hui-ling¹, GAO Li-xia¹, LI Gui-yuan², ZHU Hai-peng¹, LI Di¹, JIA Xiao-ling¹, HU Jun¹

1. Department of Hematologic Oncology , Karamay Central Hospital of Xinjiang, Xinjiang Clinical Research Center for precision medicine of digestive system tumor, Xinjiang Key Laboratory of Clinical Genetic Testing and Biomedical Information, Karamay 834000, China;
2. Department of Medical Oncology, Shanghai Tongji Hospital, Shanghai 200065, China

Received:2023-09-30 Online:2024-12-31 Published:2025-02-19
Contact: HU Jun

摘要/Abstract

摘要： 目的探讨联合检测血清脱嘌呤/脱嘧啶核酸内切酶1(APE1)及微小RNA183(miR183)在肝癌诊断中的价值。方法利用酶联免疫吸附试验(ELISA)法检测2021年3月—2022年6月克拉玛依市中心医院60例体检健康者(正常组)、180例肝癌高危患者(高危组)及60例肝癌患者(肝癌组)血清APE1 蛋白水平,实时荧光定量PCR检测3组人群的血清miR183水平,使用受试者工作特征曲线(ROC)曲线分析, 探讨联合检测APE1、miR183在肝癌诊断中的价值。结果肝癌组APE1检测结果为92.39(70.76, 418.99)IU/mL,高危组为88.96(77.27, 406.28)IU/mL,两组均高于正常组75.79(65.09, 81.97)IU/mL(P<0.001),但肝癌组与高危组之间未见明显差异(P=0.714)。肝癌组miR183相对表达量为2.35(1.02, 4.15),高危组为1.38(0.76, 3.13),正常组为0.98(0.70, 2.01),肝癌组明显高于其他两组(P≤0.001),但高危组与正常组差异无统计学意义(P=0.166)。单用APE1诊断肝癌的曲线下面积(AUC)为0.703(95%CI: 0.607~0.799),诊断临界值为94.7 IU/mL,灵敏度为50%,特异度为99.5%。单用miR183诊断肝癌的AUC为0.723(95%CI: 0.634~0.813),相对表达量的诊断临界值为1.78,灵敏度为66.7%,特异度为73.3%。联合检测APE1及miR183的AUC最大为0.829(95%CI: 0.756~0.903),灵敏度为83.3%,特异度为70.0%。结论血清APE1蛋白、miR183两个指标对肝癌诊断均有一定价值,联合检测可提高对肝癌的检出率。

关键词: 原发性肝癌, APE1, miR183, 联合检测

Abstract: Objective To investigate the value of combined detection of serum apurinic/apyrimidinic endonuclease 1 (APE1) and microRNA183 (miR183) in the diagnosis of primary hepatocellular carcinoma.Methods Enzyme-linked immunosorbent assay (ELISA) was used to detect the serum APE1 protein level in 60 healthy individuals (normal group), 180 high-risk patients with hepatocellular carcinoma (high-risk group) and 60 hepatocellular carcinoma patients (hepatocellular carcinoma group). The levels of the serum miR183 in the three groups were detected by real-time fluorescent quantitative polymerase chain reaction (RT-qPCR). Receiver operating characteristic (ROC) curve analysis was used to explore the value of combined detection of APE1 and miR183 in the diagnosis of hepatocellular carcinoma.Results The detection results of APE1 in the hepatocellular carcinomar group were 92.39 (70.76, 418.99) IU/mL, while those in the high-risk group were 88.96 (77.27, 406.28) IU/mL, both of which were higher than the normal group 75.79 (65.09, 81.97) IU/mL (P<0.001), but there was no significant difference between the hepatocellular carcinoma group and the high-risk group (P=0.714). The relative expression of miR183 in the hepatocellular carcinoma group was 2.35 (1.02, 4.15), the high-risk group was 1.38 (0.76, 3.13), and the normal group was 0.98 (0.70, 2.01). The results in hepatocellular carcinoma group were significantly higher than the other two groups (P<0.05), but there was no significant difference between the high-risk group and the normal group (P=0.166). The area under the curve (AUC) of APE1 alone in the diagnosis of hepatocellular carcinoma was 0.703 (95%CI: 0.607-0.799), the diagnostic cut-off value was 94.7 IU/mL, the sensitivity was 50%, and the specificity was 99.5%. The AUC of miR183 alone in the diagnosis of hepatocellular carcinoma was 0.723 (95%CI: 0.634-0.813), the diagnostic critical value of relative expression was 1.78, the sensitivity was 66.7%, and the specificity was 73.3%. The maximum AUC of combined detection of APE1 and miR183 was 0.829 (95%CI: 0.756-0.903), the sensitivity was 83.3%, and the specificity was 70.0%.Conclusion The two indicators of serum APE1 protein and miR183 have certain value in the diagnosis of hepatocellular carcinoma, and the combined detection of the two indicators can improve the ability to detect the primary hepatocellular carcinoma.

Key words: Primary hepatocellular carcinoma, Apurinic/apyrimidinic endonuclease 1, microRNA183, Combined detection

菅辉玲, 高丽霞, 李桂圆, 朱海鹏, 李砥, 贾晓玲, 胡军. 联合检测血清APE1、miR183在原发性肝癌诊断中的价值[J]. 肝脏, 2024, 29(12): 1498-1502.

JIAN Hui-ling, GAO Li-xia, LI Gui-yuan, ZHU Hai-peng, LI Di, JIA Xiao-ling, HU Jun. The diagnostic value of combined detection of serum APE1 and miR183 in primary hepatocellular carcinoma[J]. Chinese Hepatolgy, 2024, 29(12): 1498-1502.

/ 推荐

参考文献

[1] Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,7(3):209-249.
[2] Akateh C, Black SM, Conteh L, et al. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma[J]. World J Gastroenterol,2019,25(28):3704-3721.
[3] M ejia J C, Pasko J. Primary Liver Cancers: Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma-ScienceDirect [J]. Surg Clin North Am,2020,100(3):535-549.
[4] 罗家敏, 戴楠, 陈川, 等. 血清APE1蛋白检测在食管癌诊断中的价值[J]. 国际检验医学杂志,2019,40(22):2738-2741.
[5] 吉祖进, 张志云, 高燕, 等. APE1通过NF-κB通路调节结直肠癌PD-L1表达和细胞增殖[J]. 华中科技大学学报(医学版),2019,48(4):393-399.
[6] Hou F, Li X, Wang Y, et al. MicroRNA-183 accelerates the proliferation of hepatocyte during liver regeneration through targeting programmed cell death protein 6[J]. Genes Genomics,2022,44(8):1017-1029.
[7] Li H, Pan, X, Gui, Y, et al. Upregulation of miR-183-5p predicts worse survival in patients with renal cell cancer after surgery[J]. Cancer Biomark,2019,24:153-158.
[8] 高娟, 李盼盼. AFP、AFP-L3%与GP73联合检测对原发性肝癌的诊断价值[J]. 数理医药学杂志,2022,35(1):112-114.
[9] Antoniali G, Serra F, Lirussi L, et al. Mammalian APE1 controls miRNA processing and its interactome is linked to cancer RNA metabolism[J]. Nat Commun,2017,8(1):797.
[10] Liang W, Wei X, Li Q, et al. MicroRNA-765 enhances the anti-angiogenic effect of CDDP via APE1 in osteosarcoma[J]. J Cancer, 2017, 8(9):1542-1551.
[11] 梁丹, 冯凯祥, 张强, 等. PD-L1与APE1在乳腺癌组织中的表达及与其预后的相关性[J].实用癌症杂志,2022,37(9):1429-1432.
[12] Liu Y, Gao S, Du Q, et al. miR-146a and miR-152 in prostate cancer and clinicopathological parameters[J]. J BUON,2019,24(4):1692-1699.
[13] Luo J, Hou Y, Ma W, et al. A novel mechanism underlying alcohol dehydrogenase expression: hsa-miR-148-3p promotes ADH4 expression via an AGO1-dependent manner in control and ethanol-exposed hepatic cell [J]. Bichemi Pharmacol,2021,189:114458.
[14] Luo J, Xie M, Hou Y, et al. A novel epigenetic mechanism unravels has-miR148a-3p- mediated CYP2B6 downregulation in alcoholic hepatitis disease [J]. Biochem Pharmacol,2021,188:114582.
[15] Han T, Zheng H, Zhang J, et al. Downregulation of MUC15 by miR-183-5p.1 promotes liver tumor-initiating cells properties and tumorigenesis via regulating c-MET/PI3K/AKT/SOX2 axis[J]. Cell Death Dis,2020,13(3):200.
[16] Han H, Zhou S, Chen G, et al. ABAT targeted by miR-183-5p regulates cell functions in liver cancer [J]. Int J Biochem Cell Biol,2021,141:106116.
[17] Duan X, Li W, Hu P, et al. MicroRNA-183-5p contributes to malignant progression through targeting PDCD4 in human hepatocellular carcinoma [J]. Bioscience Reports,2020,40(10):BSR20201761.
[18] Han H, Zhou S, Chen G, et al. ABAT targeted by miR-183-5p regulates cell functions in liver cancer [J]. Int J Biochem Cell Biol,2021,141:106116.
[19] 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版)[J]. 肿瘤防治研究,2022,49(3):251-276.
[20] 卢慧, 谢正元. 肝癌无创早期诊断的研究进展[J]. 肿瘤防治研究,2023,50(1):75-79.